Home | Welcome to Contract Pharma   
Last Updated Thursday, November 27 2014
Print

Takeda, Amylin End Pact



By Gil Roth



Published December 26, 2012
Related Searches: Phase II formulation Development
Takeda Pharmaceutical Co. and Amylin Pharmaceuticals have mutually terminated their worldwide agreement to co-develop and commercialize compounds for obesity. The pact began in October 2009, .

The companies announced in August 2011 their decision to discontinue the development of pramlintide/metreleptin, an investigational combination therapy for the treatment of obesity. That joint decision was based on a commercial reassessment of the pramlintide/metreleptin program, which had been in Phase II development as a twice-a-day injection formulation. The companies have since decided to formally terminate the partnership at this time. Amylin was purchased by Bristol-Myers Squibb and AstraZeneca in June 2012.

Takeda released a statement that read, "Having greatly benefited from the Amylin team's collective experience and scientific expertise, Takeda will continue to enhance its R&D activities in the area of obesity as well as its other core therapeutic areas to meet the needs of patients."


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On